CytoMed Therapeutics (NASDAQ:GDTC) Shares Up 1% – Here’s Why

CytoMed Therapeutics Limited (NASDAQ:GDTC) shares rose 1% during trading on Thursday . The company traded as high as $0.98 and last traded at $0.98. Approximately 7,126 shares changed hands during mid-day trading, a decline of 47% from the average session volume of 13,461 shares. The stock had previously closed at $0.9699.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of CytoMed Therapeutics in a report on Friday, April 10th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, CytoMed Therapeutics presently has a consensus rating of “Sell”.

CytoMed Therapeutics Stock Up 1.0%

The company has a debt-to-equity ratio of 0.06, a quick ratio of 5.17 and a current ratio of 5.17. The company has a 50 day moving average price of $1.05 and a 200 day moving average price of $1.07.

Insider Transactions at CytoMed Therapeutics

In related news, Director Chee Kong Choo acquired 112,000 shares of CytoMed Therapeutics stock in a transaction on Wednesday, May 13th. The stock was purchased at an average cost of $1.15 per share, with a total value of $128,800.00. Following the completion of the transaction, the director directly owned 430,324 shares in the company, valued at $494,872.60. This trade represents a 35.18% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

About CytoMed Therapeutics

CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. The company is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord derived mesenchymal stem cells for cartilage injury.